Results 101 to 110 of about 21,820 (216)

Prevalence and mortality of ceftazidime/avibactam-resistant KPC-producing Klebsiella pneumoniae bloodstream infections (2018–2022) [PDF]

Funding Information: Open access funding provided by Università degli Studi di Torino within the CRUI-CARE Agreement. This research was supported by EU funding within the MUR PNRR Extended Partnership initiative on Emerging Infectious Diseases (Project ...
Bianco, Gabriele, Costa, Cristina, Bastos, Paulo, Almeida, André, Cavallo, Rossana, Boattini, Matteo, Comini, Sara, De Rosa, Francesco Giuseppe, Corcione, Silvia   +8 more
core   +1 more source

In vitro activity of ceftazidime-avibactam combination in in vitro checkerboard assays [PDF]

, 2015
Contains fulltext : 153132.pdf (Publisher’s version ) (Open Access)To evaluate the in vitro effects of the combination of ceftazidime and avibactam on the MICs of both compounds, checkerboard assays were performed for 81 clinical ...
Nichols, W.W., Melchers, M.J.B., Mouton, Johan, Melchers, MJ, van Mil, AC, Berkhout, J., Mil, A.C. van, Mouton †, J.W., Mouton, J.W., Berkhout, J, Nichols, WW   +10 more
core   +2 more sources

Activity of ceftazidime-avibactam combinations against carbapenem-resistant Klebsiella pneumoniae assessed by checkerboard method

: The aim of this study is to detect the carbapenemase type and to determine the in vitro effects of ceftazidime/avibactam-colistin, ceftazidime/avibactam-meropenem and ceftazidime/avibactam-tigecycline combinations against Carbapenem-Resistant ...
Ayten Nur Uzun, Uzun, Ayten Nur, Hilal Tanriverdi, Tanriverdi, Hilal, GENÇ, SERPİL, Serpil Genç   +5 more
core   +1 more source

Carbapenemase-producing Klebsiella pneumoniae intra-abdominal infection successfully treated with ceftazidime/avibactam plus tigecycline

, 2020
Ceftazidime/avibactam combines ceftazidime with a new beta-lactam that successfully that inhibits Amber Class A and D carbapenemases.We report a clinical case of a 61 year-old man with a carbapenemase-producing Klebsiella pneumoniae intra-abdominal ...
Mariana Guedes, Nuno Rocha-Pereira, Raquel Duro, Isabel Abreu, Telma Fonseca   +4 more
core   +1 more source

Experience with ceftazidime–avibactam treatment in a tertiary care center in Saudi Arabia

Journal of Infection and Public Health, 2018
Introduction: Carbapenem-resistant organisms have become major healthcare-associated pathogens and are responsible for significant morbidity and mortality worldwide.
Abdullah Algwizani, Mohammad Alzunitan, Ahmad Alharbi, Abdulrahman Alsaedy, Sameera Aljohani, Bassam Alalwan, Jawaher Gramish, Adel Alothman   +7 more
doaj   +1 more source

Pharmacodynamics of ceftazidime/avibactam against extracellular and intracellular forms of Pseudomonas aeruginosa

, 2017
Objectives: When tested in broth, avibactam reverses ceftazidime resistance in many Pseudomonas aeruginosa that express ESBLs. We examined whether similar reversal is observed against intracellular forms of P. aeruginosa.
Krause, K.M., Nichols, W. W., Muccioli, Giulio, Buyck, Julien, Van Bambeke, Françoise, Luyckx, C., Tulkens, Paul M.   +6 more
core   +1 more source

Ceftazidime-avibactam in the treatment of infections from carbapenem-resistant Klebsiella pneumoniae: Ceftazidime-avibactam against CR-KP infections.

Journal of global antimicrobial resistance, 2021
Clinical experience with ceftazidime-avibactam (CAZ-AVI) for the treatment of carbapenem-resistant Klebsiella pneumoniae (CR-KP) infections is not well evaluated. The aim of this study was to assess its efficacy in a single-centre cohort of patients infected with CR-KP.We conducted a retrospective observational study of consecutive patients treated for
Jie, Gu, Jie, Xu, Ting-Ting, Zuo, Yan-Bin, Chen   +3 more
openaire   +1 more source

Investigating Gram-negative bacilli isolates’ sensitivity to ceftazidime/avibactam

Background: Multidrug resistant (MDR) Gram negative organisms are becoming increasingly common. Carbapenem resistant Enterobacterales (CRE) pose a major threat and necessitate the development of new antibiotics.
Mithilesh Kumar Jha, Mukesh Kumar, Sunali, Maneesh Kumar, Nishant Ranjan   +4 more
core   +1 more source

Multicenter Study of Outcomes with Ceftazidime-Avibactam in Patients with Carbapenem-Resistant Enterobacteriaceae Infections

, 2017
Ceftazidime-avibactam is a novel cephalosporin–beta-lactamase inhibitor combination that is active against many carbapenem-resistant Enterobacteriaceae (CRE).
Safia Kuriakose, Madeline King, Kenneth Biason, Jason C. Gallagher, Vanthida Huang, Julianne Gardner, Dorothy McCoy, Nicole Harrington, Lynette Richards, Claudine El-Beyrouty, Emily Heil, Tiffany Bias, Jon Hiles   +12 more
core   +1 more source

Suboptimal ceftazidime-avibactam exposure drives sequential blaKPC mutations and intra-host coexistence of Klebsiella pneumoniae harboring distinct variants leading to persistent infection

Microbiology Spectrum
KPC-producing Klebsiella pneumoniae infections are a rising global health threat. The factors driving blaKPC mutations during treatment and their contribution to infection persistence remain unclear.
Feng Yang, Weiwei Yang, Jinghao Zhang, Chengkang Tang, Li Ding, Siquan Shen, Yanhao Zhou, Hongyu Zhao, Jiaojiao Zhou, Fupin Hu   +9 more
doaj   +1 more source